

Europe (headquarters)
Cisbio Bioassays
Phone: +33 (0)4 66 79 67 05
Fax: +33 (0)4 66 79 19 20
E-mail: bioassays@cisbio.com

Japan
Sceit Medical Labo K.K.
Phone: +81 (0)3 5510 2932
Fax: +81 (0)3 5510 0130
E-mail: reagent@sceitmedilabo.co.jp

USA
Cisbio US, Inc.
Phone : 888 963 4567
Fax : 781 687 1500
E-mail : htrfi nfo@cisbio.us



Tag-lite® CCK2 stable cell line

www.htrf.com


Cell line Information

For in vitro research use only
Version rev 2 (Sept. 2011)

Cell line code	C1SU1CCK2
Storage	Liquid nitrogen
Batch	05 Jan 2010
Passages number	9
Total cells	9 millions/vial

Target information

Target:	Cholecystokinin CCK2 receptor This receptor is fused in N-term position with SNAP-tag.
Species:	Human
NCBI accession number:	NM_176875.2



Cell culture information

Cellular background:	HEK293 Adherent
Culture medium:	D-MEM (Invitrogen #31966) ,10%FBS, 1% non essentials amino acids (Invitrogen #11140-035), 50U/ml penicillin, 50µg/ml streptomycin, 2mM Hepes, 0.6mg/mL G418
Growth conditions:	37°C, 5%CO2
Freezing medium:	90% FCS+10%DMSO

Thawing procedure:

Thaw the vials of cryopreserved cells rapidly in a water bath at 37°C. Carefully transfer the cells to a cell culture vessel containing the appropriate volume of pre-warmed culture medium without G418 so that cell density reaches $4 \cdot 10^4$ to $8 \cdot 10^4$ cells/cm². The day after, ensure that cells have properly attached and carefully replace with fresh culture medium supplemented with G418. Allow cells to grow until 80% confluency then transfer in a new cell culture vessel. Note that final DMSO concentration must not exceed 0.5%.

Subculturing:

Once cells have reached 80% confluency, carefully remove and discard culture medium. Rinse once with PBS then add the appropriate volume of cell dissociation solution. Observe under microscope until cell layer is detached. Add growth medium, then centrifuge 3min at 180g. Replace supernatant by fresh cell culture medium and pipet up and down to remove aggregates. Count cells, and split in a new culture vessel with a ratio 1:5 maximum. Replace medium once or twice a week.

Biosafety and compliance

Biosafety level: 2

Warning:

This product contains material of biological origin. Use for research purposes only. Do not use in humans or for diagnostic purposes. The purchaser assumes all risk and responsibility concerning reception, handling and storage. The use of the cell line will be done with appropriate safety and handling precautions to minimize health and environmental impact. The product is genetically modified and must be used according to biosafety level S2. The purchaser declares the authorization to manipulate GMO and agrees to apply all guidelines, laws and regulations.

Tag-lite stable cell line validation

Tag-lite cell line is a comprehensive cellular platform certified for:
Ligand binding assay Receptor dimerization assays
cAMP assay Internalization assay

For each application a protocol can be downloaded on www.htrf.com

Copyright © 2011 Cisbio Bioassays, France

HTRF®, Tag-lite®, and the HTRF® logo are trademarks belonging to Cisbio Bioassays.

HTRF® products are manufactured under one or more of the following patents and foreign equivalent : EP 0 180 492 / US 4,927,923 / US 5,220,012 / US 5,432,101 - EP 0 321 353 / US 5,457,185 / US 5,534,622 / US 5,346,996 / US 5,162,508 - EP 0 539 477 / US 5,512,493 - EP 0 539 435 / US 5,627,074 - EP 0 569 496 / US 5,527,684. Cisbio Bioassays hereby grants to those buying HTRF® products from Cisbio Bioassays or its affiliates / distributors, a worldwide, non-exclusive, royalty-free, limited license to use HTRF® technology with said products for in-house life science research only. Signal amplification and correction using HTRF® technology are covered by the following U.S. patents or patent applications and foreign equivalents : US 5,512,493 - US 5,527,684 - US 6,352,672.

SNAP-tag and CLIP-tag are trademarks exclusively licensed to New England Biolabs. Plasmids encoding SNAP-tag and CLIP-tag and their substrates are made under license from New England Biolabs and may be covered by one or more of the following published patent applications filed internationally in US, EP and JP and also in additional jurisdictions : WO2002/083937 WO2004/031405 WO2004/104588 WO2004/031404 WO2005/085470 WO2008/012296 US, WO2008/122604 and EP patents 1410023 and 1696234.